NCT06526377Phase 2Not yet recruiting

Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy

Study sponsor: XBiotech, Inc. · XBIT

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2028-09Estimated
Enrollment · participants150Estimated
Source updated2026-05-14Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Assessment of Spondyloarthritis International Society (ASAS) criteria will be used to determine proportion of subjects achieving 40% Improvement (ASAS40 response)

+ Updated value

measure: Percentage of participants achieving ASAS40.

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit
− Previous value

count: 60; type: ESTIMATED

+ Updated value

count: 150; type: ESTIMATED

Primary completion date

Recorded edit
− Previous value

2027-02-28

+ Updated value

2028-09

Check registry source

· 1 field changed

Primary completion date

Recorded edit
− Previous value

2025-02-28

+ Updated value

2027-02-28

Check registry source